TY - JOUR
T1 - Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
AU - Klebanov, Nikolai
AU - Pahalyants, Vartan
AU - Murphy, William S.
AU - Theodosakis, Nicholas
AU - Zubiri, Leyre
AU - Klevens, R. Monina
AU - Kwatra, Shawn G.
AU - Lilly, Evelyn
AU - Reynolds, Kerry L.
AU - Semenov, Yevgeniy R.
N1 - Funding Information:
This work was conducted with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center (BR; National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102), and financial contributions from Harvard University and its affiliated academic health care centers.
Funding Information:
We thank Stacey Duey and Celina Li of the Research Patient Data Registry for their help with patient chart data access. We also thank Bernard Rosner of Harvard Medical School for his valuable guidance for the study design and analysis. This work was conducted with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center (BR; National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102), and financial contributions from Harvard University and its affiliated academic health care centers. This study was approved by the Institutional Review Boards at Mass General Brigham (Protocol 2020P001191) and Massachusetts Department of Public Health (Protocol 1606024?2).
Publisher Copyright:
© 2021 AlphaMed Press
PY - 2021/5
Y1 - 2021/5
N2 - Objective: The aim of this study was to determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs). Materials and Methods: This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020. Results: The mean age was 66.6 years, and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility. Conclusion: ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic.
AB - Objective: The aim of this study was to determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs). Materials and Methods: This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020. Results: The mean age was 66.6 years, and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility. Conclusion: ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic.
UR - http://www.scopus.com/inward/record.url?scp=85104503113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104503113&partnerID=8YFLogxK
U2 - 10.1002/onco.13768
DO - 10.1002/onco.13768
M3 - Article
C2 - 33783099
AN - SCOPUS:85104503113
SN - 1083-7159
VL - 26
SP - e898-e901
JO - Oncologist
JF - Oncologist
IS - 5
ER -